Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Discovered in collaboration with Kotobuki Pharmaceutical, gilteritinib is a receptor tyrosine kinase inhibitor of FLT3 and AXL that are known to be involved in the growth of cancer cells.

The randomised, double-blind, placebo-controlled, multi-centre Phase III trial is designed to evaluate gilteritinib as a maintenance therapy over two years after hematopoietic stem cell transplants (HCT).

MORPHO will include subjects who are FLT3 internal tandem duplication (ITD) mutation-positive (FLT3/ITD+) and in remission following induction therapy.

Astellas Pharma oncology development senior vice-president and global therapeutic area head Steven Benner said: "The initiation of the MORPHO trial is another significant milestone for Astellas and for patients as therapeutic options can be very limited for this FLT3+ AML population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The initiation of the MORPHO trial is another significant milestone for Astellas and for patients as therapeutic options can be very limited for this FLT3+ AML population."

“We are committed to patients with FLT3+ AML and currently have underway four Phase III trials to explore the potential benefit of gilteritinib for patients suffering from such an aggressive form of blood cancer characterised by both genetic and resistance mutations.”

The MORPHO trial is currently being conducted in partnership with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) and its primary endpoint is relapse-free survival (RFS).

Gilteritinib is reported to have demonstrated inhibitory activity against common FLT3 mutation types, FLT3 and FLT3 tyrosine kinase domain (TKD).

Additionally, the drug candidate is also said to inhibit AXL that is reportedly associated with therapeutic resistance.

Image: Myeloblasts with Auer rods seen in acute myeloid leukaemia. Photo: courtesy of Paulo Henrique Orlandi Mourao.